Literature DB >> 16798621

Therapeutic drug monitoring in HIV treatment: a literature review.

Benjamin Z Wertheimer1, Kenneth A Freedberg, Rochelle P Walensky, Yazdan Yazdanapah, Elena Losina.   

Abstract

PURPOSE: Therapeutic drug monitoring (TDM) is the practice of managing plasma drug concentrations. This intervention can potentially improve inadequate antiretroviral dosing in the treatment of HIV infection. Our objective was to review the evidence regarding TDM in HIV management.
METHOD: We searched MEDLINE using the following key words: therapeutic drug monitoring, HIV infection, pharmacokinetics, antiretroviral therapy, protease inhibitors, antiretroviral-naïve, antiretroviral-experienced, and salvage therapy. inclusion criteria required definition of optimal concentration thresholds and measures of treatment effectiveness at these targets.
RESULTS: Our search yielded 39 studies. 11 studies met inclusion criteria. 4 studies compared efficacy of TDM to standard of care (SOC) interventions via randomized clinical trials and were grouped as "interventional." 7 studies retrospectively defined thresholds from observed differences in outcome and were grouped as "observational." 3 interventional studies targeted similar indinavir concentrations (Cmin = 0.10-0.15 mg/L). 2 of these studies increased achievement of target serum levels and percentages of undetectable viral load (23%-41%, p < or = .009) with TDM implementation.
CONCLUSION: TDM can effectively target antiretroviral threshold concentrations and improve virologic suppression in some cases. Further work is needed to define plasma thresholds and assess the value of TDM in HIV management.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16798621     DOI: 10.1310/hct.2006.7.2.004

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  13 in total

1.  Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Authors:  Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng
Journal:  Rapid Commun Mass Spectrom       Date:  2018-03-15       Impact factor: 2.419

2.  Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings.

Authors:  Monica Gandhi; Qiyun Yang; Peter Bacchetti; Yong Huang
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

Review 3.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

Review 4.  Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.

Authors:  Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

5.  Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Authors:  Qing Ma; Barry S Zingman; Amneris E Luque; Margaret A Fischl; Barbara M Gripshover; Charles S Venuto; Robin DiFrancesco; Alan Forrest; Gene D Morse
Journal:  Ther Drug Monit       Date:  2011-06       Impact factor: 3.681

6.  Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda.

Authors:  Peter K Olds; Julius P Kiwanuka; Denis Nansera; Yong Huang; Peter Bacchetti; Chengshi Jin; Monica Gandhi; Jessica E Haberer
Journal:  AIDS Care       Date:  2014-12-06

7.  Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.

Authors:  Michael Neely; Roger Jelliffe
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126

Review 8.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Protease inhibitor levels in hair strongly predict virologic response to treatment.

Authors:  Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Stephen J Gange; Kathryn Anastos; Alexandra Levine; Charles L Hyman; Mardge Cohen; Mary Young; Yong Huang; Ruth M Greenblatt
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

10.  Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).

Authors:  Albert Y Liu; Qiyun Yang; Yong Huang; Peter Bacchetti; Peter L Anderson; Chengshi Jin; Kathy Goggin; Kristefer Stojanovski; Robert Grant; Susan P Buchbinder; Ruth M Greenblatt; Monica Gandhi
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.